100 μg KIO-301
KIO-301-2101
Phase 2 small_molecule active
Quick answer
100 μg KIO-301 for Retinitis Pigmentosa is a Phase 2 program (small_molecule) at KIORA PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- KIORA PHARMACEUTICALS INC
- Indication
- Retinitis Pigmentosa
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active